Continuous Sleep Monitoring Using the Withings Sleep Mat to Assess Mean Disease Alleviation in <scp>OSA</scp>

ABSTRACT Objective This pilot study aims to demonstrate the feasibility of continuous sleep monitoring using the Withings Sleep Mat (WSM) and to illustrate Mean Disease Alleviation (MDA) as a potential metric for assessing real‐world treatment effectiveness among patients with obstructive sleep apnea (OSA) treated with hypoglossal nerve stimulation (HGNS) or continuous positive airway pressure (CPAP). Methods Patients treated with CPAP or HGNS therapy were prospectively recruited. The WSM provided nightly estimations of sleep metrics including AHI, total sleep time, and other non‐apneic metrics over 30‐ and 90‐day periods. MDA integrating treatment efficacy and adjusted compliance was calculated as a composite measure of real‐world treatment effectiveness. Results A total of 29 patients (mean age 59.8 years; 66% male; 93% White) were included, with 15 treated with CPAP and 14 with HGNS. The 90‐day MDA, calculated using continuous AHI monitoring, was 36.05% for CPAP and 24.06% for HGNS ( p = 0.20). Mean MDA using single‐night sleep study (HGNS) or CPAP download (CPAP) was 81.72% (14.81) among CPAP patients and 51.18% (26.69) among HGNS patients ( p = 0.002). HGNS patients experienced more awakenings (3.23 vs. 2.56, p = 0.031) and snoring episodes (2.86 vs. 1.79, p = 0.029) per night during the 30‐day interval. Conclusion This study demonstrates the feasibility of calculating MDA through continuous, non‐invasive home monitoring using the WSA, offering a more comprehensive assessment of OSA treatment effectiveness than single‐night studies alone. These findings support further evaluation of continuous home‐based monitoring and integrated metrics like MDA to inform personalized therapy selection and long‐term management. Level of Evidence 4.